Drugs that contain Paclitaxel
1. List of Abraxane drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7923536 | ABRAXIS BIOSCIENCE | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(10 months from now) | |
| US8138229 | ABRAXIS BIOSCIENCE | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(10 months from now) | |
| US8314156 | ABRAXIS BIOSCIENCE | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(10 months from now) | |
|
US7923536
(Pediatric) | ABRAXIS BIOSCIENCE | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(1 year, 4 months from now) | |
|
US8314156
(Pediatric) | ABRAXIS BIOSCIENCE | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(1 year, 4 months from now) | |
|
US8138229
(Pediatric) | ABRAXIS BIOSCIENCE | Compositions and methods of delivery of pharmacological agents |
Jun, 2024
(1 year, 4 months from now) | |
| US7820788 | ABRAXIS BIOSCIENCE | Compositions and methods of delivery of pharmacological agents |
Oct, 2024
(1 year, 8 months from now) | |
|
US7820788
(Pediatric) | ABRAXIS BIOSCIENCE | Compositions and methods of delivery of pharmacological agents |
Apr, 2025
(2 years from now) | |
| US7758891 | ABRAXIS BIOSCIENCE | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(3 years from now) | |
| US9101543 | ABRAXIS BIOSCIENCE | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(3 years from now) | |
| US8268348 | ABRAXIS BIOSCIENCE | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2026
(3 years from now) | |
| US8034375 | ABRAXIS BIOSCIENCE | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(3 years from now) | |
|
US9101543
(Pediatric) | ABRAXIS BIOSCIENCE | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(3 years from now) | |
|
US8268348
(Pediatric) | ABRAXIS BIOSCIENCE | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(3 years from now) | |
|
US7758891
(Pediatric) | ABRAXIS BIOSCIENCE | Combinations and modes of administration of therapeutic agents and combination therapy |
Aug, 2026
(3 years from now) | |
|
US8034375
(Pediatric) | ABRAXIS BIOSCIENCE | Combinations and modes of administration of therapeutic agents and combination therapy |
Feb, 2027
(4 years from now) | |
| US9597409 | ABRAXIS BIOSCIENCE | Methods of treating cancer |
Mar, 2032
(9 years from now) | |
| US9393318 | ABRAXIS BIOSCIENCE | Methods of treating cancer |
Mar, 2032
(9 years from now) | |
|
US9393318
(Pediatric) | ABRAXIS BIOSCIENCE | Methods of treating cancer |
Sep, 2032
(9 years from now) | |
|
US9597409
(Pediatric) | ABRAXIS BIOSCIENCE | Methods of treating cancer |
Sep, 2032
(9 years from now) | |
| US9511046 | ABRAXIS BIOSCIENCE | Methods of treating pancreatic cancer |
Jan, 2034
(10 years from now) | |
|
US9511046
(Pediatric) | ABRAXIS BIOSCIENCE | Methods of treating pancreatic cancer |
Jul, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M | Dec 6, 2022 |
| Pediatric Exclusivity (PED) | Jun 6, 2023 |
Market Authorisation Date: 07 January, 2005
Treatment: Treatment of pancreatic cancer; Treatment of lung cancer; Treatment of breast cancer
Dosage: POWDER;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic